Status:
COMPLETED
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial
Lead Sponsor:
Allergan
Conditions:
Overactive Bladder
Eligibility:
All Genders
60+ years
Phase:
PHASE4
Brief Summary
This study will evaluate the cerebrospinal fluid levels of trospium chloride (Sanctura XR®) and oxybutynin immediate release (Oxybutynin IR) on memory performance in patients with overactive bladder a...
Eligibility Criteria
Inclusion
- Patient presents symptoms of overactive bladder
- Patient has age associated memory impairment
- No acute or unstable medical conditions
Exclusion
- History of alcohol or substance abuse within 1 year prior to study
- Has donated in excess of 500mL of blood or plasma in the 30 days prior to study
- Has known bleeding disorder (hemophilia)
- Previous abdominal bypass surgery for obesity
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01178827
Start Date
August 1 2010
End Date
March 1 2011
Last Update
February 26 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Salt Lake City, Utah, United States